WuXi STA Completes Acquisition of BMS’ Mfg Facility in Switzerland

By Miranda Greenberg -

August 5, 2021

WuXi STA, a CDMO and subsidiary of WuXi AppTec, has completed its acquisition of a drug-product manufacturing facility in Couvet, Switzerland from Bristol-Myers Squibb (BMS).

WuXi STA first announced its plans to purchase the facility earlier this year (February 2021). The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, the site has commercial-scale production capacity for capsule and tablet dosage forms.

Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America, and Europe, including the recently announced US site in Middletown, Delaware. In June (June 2021), WuXi STA named Middletown, Delaware as the location of its new pharmaceutical manufacturing campus, which is expected to open in 2024. The future Middletown site will become WuXi STA’s second site in the US and will have clinical- and commercial-scale manufacturing capabilities.

Source: Bristol-Myers Squibb and WuXi STA